

## Curriculum Vitae

Personal information **Marko Korenjak**

### Work experience

---

1. Employer: European Liver Patients Association
  - Start date: 25th November 2018
  - End date: current
  - Position: ELPA President
  - Activities: leading all activities of international patient association
  - Country: Belgium
2. Employer: European Liver Patients Association
  - Start date: 1st June 2016
  - End date: 25th November 2018
  - Position: ELPA vice president for activities and development
  - Activities: development of new projects and activities
  - Country: Belgium
3. Employer: Association SLOVENIA HEP
  - Start date: 1st March 2016
  - End date: current
  - Position: Director and chief executive
  - Activities: Monitoring off patient activities in Slovenia.
  - Country: Slovenia
4. Employer: Education, consulting and psychotherapy Marko Korenjak s.p.
  - Start date: 1st March 2003
  - End date: 1st March 2016
  - Position: Director and chief executive
  - Activities: leading workshops on communication, presentations and work psychology.
  - Country: Slovenia
5. Employer: ZM Agenta d.o.o.
  - Start date: 1st March 1999
  - End date: 1st March 2003
  - Position: Assistant to the director
  - Activities: management of ISO standard as internal analyst.
  - Country: Slovenia

### Education and training

---

1. Subject: Third Master Degree
  - Start date: October 2023
  - End date: June 2024
  - Qualification: Master of International Patient Advocacy
  - Organisation: Catholic University of the Sacred Heart
  - Country: Italy
2. Subject: Second Master Degree
  - Start date: October 2018
  - End date: January 2022
  - Qualification: Master of International relations and Diplomacy
  - Organisation: Faculty for Government and European Studies
  - Country: Slovenia
3. Subject: First Master Degree
  - Start date: October 2014
  - End date: September 2016
  - Qualification: Master of Business and Management
  - Organisation: Faculty for business and management Novo mesto
  - Country: Slovenia

### Additional information

---

#### Publications

Allaire, Manon; Bruix, Jordi; Korenjak, Marko; Manes, Sarah; Maravic, Zorana; Reeves, Helen et al. (2022): What to do about hepatocellular carcinoma: Recommendations for health authorities: An International Liver Cancer Association Advocacy Document. In JHEP Reports, p. 100578.

Ballester, María Pilar; Laue, Tobias; Meoli, Lilianeleny; Uson, Eva; Mutschler, Frauke; Grabitz, Carl; McLin, Valérie; D'Antiga, Lorenzo; Pujadas, Montserrat; Carvalho-Gomes, Ângela; (2024): FRI-171 Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation. In Journal of Hepatology 80.0, pp. S700-700.

Caraceni, Paolo; Vargas, Victor; Solà, Elsa; Alessandria, Carlo; Wit, Koos de; Trebicka, Jonel et al. (2021): The use of rifaximin in patients with cirrhosis. In Hepatology 74 (3), pp. 1660-1673.

Carol, Marta; Perez, Martina; Solà, Elsa; Cervera, Marta; Martinez, Sara; Juanola, Adria et al. (2022): STIGMATIZATION IS COMMON IN PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE AND CORRELATES WITH QUALITY OF LIFE. In Journal of hepatology 77, S512-S513.

Carol, Marta; Pérez-Guash, Martina; Solà, Elsa; Cervera, Marta; Martínez, Sara; Juanola, Adrià et al. (2022): Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. In *PloS one* 17 (4), e0265153.

Clearfield, Elizabeth; Miller, Veronica; Nadglowski, Joseph; Barradas, Katherine; Al Naber, Jennifer; Sanyal, Arun J. et al. (2021): coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. In *Hepatology communications* 5 (5), pp. 774–785.

Fabrellas, Núria; Carol, Marta; Palacio, Ester; Aban, Marites; Lanzillotti, Tommaso; Nicolao, Gea et al. (2020): Nursing care of patients with cirrhosis: the LiverHope nursing project. In *Hepatology* 71 (3), pp. 1106–1116.

Francque, Sven M.; Marchesini, Giulio; Kautz, Achim; Walmsley, Martine; Dörner, Rebecca; Lazarus, Jeffrey V. et al. (2021): Non-alcoholic fatty liver disease: A patient guideline. In *JHEP Reports* 3 (5), p. 100322.

Ghany, Marc G.; Buti, Maria; Lampertico, Pietro; Lee, Hannah M.; Berg, Thomas; Brunetto, Maurizia R. et al. (2023): Guidance on Treatment Endpoints and Study Design for Clinical Trials Aiming to Achieve Cure in, Chronic Hepatitis B and D-Report from the 2022 AASLD-EASL HBV/HDV Treatment Endpoints Conference. In *Journal of hepatology*.

Ginès, Pere; Thiele, Maja; Graupera, Isabel; Serra-Burriel, Miquel; Knekt, Robert J. de; Lammert, Frank et al. (2023): Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project. In *Nature Medicine* 29 (4), pp. 774–775.

Ginès, Pere; Guha, Indra Neil; Fabrellas, Núria; Allen, Alina M.; Angeli, Paolo; Serra-Burriel, Miquel; Arslanow, Anita; Brouwer, Willem Pieter; Caballeria, Llorenç; Carol, Marta; (2025): Liver Health: An Emerging Concept. In *Gastroenterology*.

Graupera, Isabel; Thiele, Maja; Ma, Ann T.; Serra-Burriel, Miquel; Pich, Judit; Fabrellas, Nuria et al. (2023): LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries (vol 22, 1385, 2022). In *BMC Public Health* 23 (1).

Graupera, Isabel; Thiele, Maja; Ma, Ann T.; Serra-Burriel, Miquel; Pich, Judit; Fabrellas, Núria et al. (2022): LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. In *BMC Public Health* 22 (1), pp. 1–10.

Graupera, Isabel; Thiele, Maja; Ma, Ann T.; Serra-Burriel, Miquel; Pich, Judit; Fabrellas, Núria et al. (2023): Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. In *BMC Public Health* 23 (1), p. 923.

Graupera, Isabel; Thiele, Maja; Castera, Laurent; Pera, Guillem; Piano, Salvatore; Soria, Anna; Fabrellas, Núria; Torán, Pere; Chacón, Carla; Bech, Katrine; (2025): LBO-005 High prevalence of undiagnosed liver fibrosis in the adult European population driven by metabolic risk factors and alcohol consumption. results from the prospective liverscreen cohort in 30,541 subjects. In *Journal of Hepatology* 82.0, pp. S11–S12.

Kaplan, Alyson; Korenjak, Marko; Brown Jr, Robert S. (2023): Post-liver transplantation patient experience. In *Journal of hepatology* 78 (6), pp. 1234–1244.

Korenjak, Dragica; Plenković, Mario; Korenjak, Marko (2013): Communication science in network marketing (NM): Alma mater Europaea-European Centre.

Korenjak, Marko (2007): Sledi psihonevroimunologije v nevolingvističnem programiranju (NLP). In *Kairos–Slovenska revija za psihoterapijo* 1 (1-2).

Korenjak, Marko (2014): 336 dni upanja : zdravljenje hepatitisa C s kemoterapevtikom.

Korenjak, Marko (2016): Analiza promocije zdravja zaposlenih v slovenskih občinah: magistrska naloga. M. Korenjak.

Korenjak, Marko (2017): Prikaz knjige: Ule, Mirjana. 2009. Psihologija komuniciranja in medosebnih odnosov. Ljubljana: Fakulteta za družbene vede, 430 str. In *Informatologia* 50 (1-2), pp. 105–106.

Korenjak, Marko (2020): Globalna zdravstvena diplomacija: magistrsko delo. Nova Univerza-Fakulteta za državne in evropske študije.

Korenjak, Marko; Radovanović, Karolina (2007): Spoznavni večer študentov psihoterapije in propedeutike ter podelitev ZIGI-jev 2007. In *Kairos–Slovenska revija za psihoterapijo* 1 (3-4).

Kondili, Loreta A; Lazarus, Jeffrey V; Jepsen, Peter; Murray, Frank; Schattenberg, Jörn M; Korenjak, Marko; Craxi, Lucia; Buti, Maria; (2024): Inequities in primary liver cancer in Europe: the state of play. In *Journal of hepatology* 80.0 (4.0), pp. 645–660.

Krag, Aleksander; Buti, Maria; Lazarus, Jeffrey V.; Allen, Alina M.; Bowman, Jacqueline; Burra, Patrizia et al. (2023): Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives. In *Journal of hepatology*.

Kucis, Vlasta (2013): Communication science in network marketing (NM)/Komunikologija u poslovnom mrežnom marketingu. In *Media, Culture, and Public Relations* 4 (2), p. 201.

Kucis, Vlasta (2013): Dragica Korenjak, Mario Plenkovic, Marko Korenjak: Communication science in network marketing (NM)/Komunikologija u poslovnom mrežnom marketingu. In *Informatologia* 46 (2), p. 175.

Kučiš, Vlasta (2013): Prikaz knjige: Dragica Korenjak, Mario Plenković, Marko Korenjak: Communication science in network marketing (NM)/Komunikologija u poslovnom mrežnom marketingu. In *Media, Culture, and Public Relations* 4 (2), pp. 201–203.

Laue, Tobias; Ballester, Maria Pilar; Meoli, Lily; Grabitz, Carl; Uson, Eva; McLin, Valerie; Pujadas, Montserrat; Carvalho-Gomes, Ângela; Sahuco, Ivan; Bono, Ariadna; (2025): Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults. In *Transplantation Direct* 11.0 (5.0), pp. e1787.

Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Nouredin, Mazen et al. (2023): A global research priority agenda to advance public health responses to fatty liver disease. In *Journal of hepatology* 79 (3), pp. 618–634.

Lazarus, Jeffrey V.; Mark, Henry E.; Anstee, Quentin M.; Arab, Juan Pablo; Batterham, Rachel L.; Castera, Laurent et al. (2022): Advancing the global public health agenda for NAFLD: a consensus statement. In *Nature Reviews Gastroenterology & Hepatology* 19 (1), pp. 60–78.

Méndez-Sánchez, Nahum; Bugianesi, Elisabetta; Gish, Robert G.; Lammert, Frank; Tilg, Herbert; Nguyen, Mindie H. et al. (2022): Global multi-stakeholder endorsement of the MAFLD definition. In *The lancet Gastroenterology & hepatology* 7 (5), pp. 388–390.

Možina, Miran; Pastirk, Samo (2007): Ob rojstvu Kairosa–Slovenske revije za psihoterapijo. In *Kairos–Slovenska*

revija za psihoterapijo 1 (1-2).

Pilar Ballester, Maria; Laue, Tobias; Meoli, Lilianeleny; Uson, Eva; Mutschler, Frauke; Grabitz, Carl; McLin, Valerie; D'Antiga, Lorenzo; Pujadas, Montserrat; Carvalho-Gomes, Angela; (2024): Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation. In JOURNAL OF HEPATOLOGY 80.0, pp. S700-S700.

Plenković, Mario (2017): NEXT EUROPE 8. Juni 2017 14: 00-18: 00 Uhr Österreichische Botschaft Berlin Stauffenbergstraße 1 10785 Berlin, Deutschland. In Media, Culture, and Public Relations 8 (1), p. 102.

Pose, Elisa; Solà, Elsa; Lozano, Juan J.; Juanola, Adrià; Sidorova, Julia; Zaccherini, Giacomo et al. (2022): Treatment with simvastatin and rifaximin restores the plasma metabolomic profile in patients with decompensated cirrhosis. In Hepatology communications 6 (5), pp. 1100-1112.

Rabal, Gemma; Lecuona, Itziar de; Korenjak, Marko; Coenraad, Minneke (2020): D8. 3 Public engagement strategy to design MICROB-PREDICT along with the need of patients.

Rajko, Bojan Varjačić; Možina, Miran; Babič, Miran; Bohak, Janko; Burgar, Darja; Černetič, Miha et al. (2010): Slovenska revija za psihoterapijo Slovenian Journal of Psychotherapy.

Rinella, Mary E.; Lazarus, Jeffrey V.; Ratzl, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha et al. (2023): A multi-society Delphi consensus statement on new fatty liver disease nomenclature. In Annals of Hepatology, p. 101133.

Serra-Burriel, Miquel; Juanola, Adrià; Serra-Burriel, Feliu; Thiele, Maja; Graupera, Isabel; Pose, Elisa et al. (2023): Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. In The Lancet.

Sharrock, Katherine C.; Noori, Teymur; Axelsson, Maria; Buti, Maria; Diaz, Asuncion; Fursa, Olga et al. (2022): Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. In PLOS Global Public Health 2 (8), e0000841.

Sharrock, Katherine C.; Noori, Teymur; Axelsson, Maria; Buti, Maria; Diaz, Asuncion; Fursa, Olga et al. (2023): Correction: Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. In PLOS Global Public Health 3 (5), e0001907.

Shiha, Gamal; Korenjak, Marko; Casanovas, Teresa; Mooney, Vicki; Sigurðardóttir, Sólveig; Koulla, Yiannoula; Soliman, Reham (2022): MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. In Journal of hepatology 77 (6), pp. 1717-1719.

Shiha, Gamal; Korenjak, Marko; Eskridge, Wayne; Casanovas, Teresa; Velez-Moller, Patricia; Högström, Sari et al. (2021): Redefining fatty liver disease: an international patient perspective. In The lancet Gastroenterology & hepatology 6 (1), pp. 73-79.

Solà, Elsa; Pose, Elisa; Campion, Daniela; Piano, Salvatore; Roux, Olivier; Simon-Talero, Macarena et al. (2021): Endpoints and design of clinical trials in patients with decompensated cirrhosis: position paper of the LiverHope Consortium. In Journal of hepatology 74 (1), pp. 200-219.

Torp, Nikolaj; Israelsen, Mads; Coenraad, Minneke; Papp, Maria; Shawcross, Debbie; Korenjak, Marko; Angeli, Paolo; Laleman, Wim; Juanola, Adria; Gines, Pere; (2024): Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL-a randomised clinical biomarker validation trial. In Bmj Open 14.0 (2.0), pp. e079309.

Torp, Nikolaj; Israelsen, Mads; Coenraad, Minneke; Papp, Mária; Shawcross, Debbie L; Korenjak, Marko; Angeli, Paolo; Laleman, Wim; Juanola, Adria; Ginès, Pere; (2024): Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL-a study protocol of a randomised clinical biomarker validation trial. In .

Tu, Thomas; Yussf, Nafisa; Tran, Lien; Ngo, Kim; Wang, Su; Mondel, Adi; Purcell, Isabelle; Chen, Jacki; Lo, Wendy; Anshah, Bright; (2025): Best practices for engaging with affected communities: chronic hepatitis B as a case study. In Infectious Diseases of Poverty 14.0 (1.0), pp. 18.

Vlasta, Kučič (2013): Prikaz knjige: Dragica Korenjak, Mario Plenković, Marko Korenjak: Communication science in network marketing (NM)/Komunikologija u poslovnom mrežnom marketingu. In Informatologia 46 (2), pp. 175-176.

## Projects

Between 2016 and 2025, the European Liver Patients' Association (ELPA) has participated in a total of **20 European collaborative research projects**. These projects have been funded under major EU frameworks including Horizon 2020, Horizon Europe, the Innovative Health Initiative (IHI), Erasmus+, and EIT Health. Collectively, these projects represent a **combined research investment of more than €200 million** and involve **over 200 collaborating institutions**, ranging from leading academic centers and clinical hospitals to patient organizations and technology partners across Europe.

As **President of ELPA**, I have overseen ELPA's strategic involvement in these projects and ensured that the patient voice is not only heard but actively shapes research direction and implementation. In our projects, ELPA plays a central role by representing the perspective of liver patients and leading or co-leading work packages dedicated to **communication, dissemination, stakeholder engagement, and public outreach**. We ensure that scientific innovations and policy developments in liver health are not only shared broadly but are also shaped by real-world patient experience and need.

The projects span a wide range of topics. Several focus on **developing artificial intelligence tools** for early diagnosis and treatment planning in liver disease, including LIVERAIM, LEOPARD, and GRIPonMASH. Others explore **liver cancer, biomarker discovery, and personalized medicine**, such as THRIVE, GENIAL, ESCALON, and GALAXY. Projects like MICROB-PREDICT and A-TANGO aim to improve outcomes in cirrhosis and acute-on-chronic liver failure, while HL4EU, LiverScreen, and FisPlat address prevention, early detection, and public health strategies.

Through our sustained involvement, ELPA has become a **key strategic partner in European health research**, helping to co-create policies, digital tools, and clinical innovations that are grounded in patients' needs and lived experiences. These collaborations have also allowed us to build extensive expertise in project coordination and stakeholder engagement, solidifying ELPA's role as one of respected patient-led organizations in the field of liver health across Europe.

## Memberships

In **May 2024**, I was honored to receive the **"Rising Star Made with Patients" Award**, issued by **Patient Focused Medicines Development (PFMD)**. This award recognizes individuals who demonstrate exceptional dedication to integrating patient perspectives into all aspects of healthcare. It celebrates innovation and leadership in advancing patient-centered approaches in the development of medicines and health services. Being selected as a recipient reflects ELPA's broader commitment to embedding the patient voice into regulatory, scientific, and clinical

frameworks across Europe.

Earlier, in **September 2017**, I was recognized by the **Economist Intelligence Unit** as one of the **HCV Change Makers**—a global initiative spotlighting individuals and organizations making significant contributions to the elimination of hepatitis C. I was one of 18 individuals recognized for creative and impactful work in areas such as screening, multi-stakeholder engagement, and the use of technology to overcome persistent challenges in HCV policy and practice. This recognition validated ELPA's efforts in driving awareness and concrete change in viral hepatitis elimination strategies.

#### Other Relevant Information

I am a patient representative.